[go: up one dir, main page]

AR087749A1 - Anticuerpos anti-xcr1 humano - Google Patents

Anticuerpos anti-xcr1 humano

Info

Publication number
AR087749A1
AR087749A1 ARP120103217A ARP120103217A AR087749A1 AR 087749 A1 AR087749 A1 AR 087749A1 AR P120103217 A ARP120103217 A AR P120103217A AR P120103217 A ARP120103217 A AR P120103217A AR 087749 A1 AR087749 A1 AR 087749A1
Authority
AR
Argentina
Prior art keywords
xcr1
human antibodies
amino acid
binds
seq
Prior art date
Application number
ARP120103217A
Other languages
English (en)
Inventor
Sakamoto Yoshimasa
Nishimura Miyuki
Kawano Tetsu
Sawa Yukihisa
Imai Toshio
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR087749A1 publication Critical patent/AR087749A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un objeto de la presente es proporcionar un anticuerpo monoclonal que se una al XCR1 humano, donde la anticuerpo se una a epítopos lineales o discontinuos que comprendan al menos tres aminoácidos seleccionados del grupo constituido por el 8º, 11º, 12º, 13º, 14º, 16º, 17º, 22º, 23º, 176º y 177º aminoácido de la secuencia de aminoácidos de la SEQ ID Nº 91. Composición farmacéutica, método para tratar una enfermedad inmunitaria, ácido nucleico.
ARP120103217A 2011-09-01 2012-08-30 Anticuerpos anti-xcr1 humano AR087749A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530194P 2011-09-01 2011-09-01
US201261659637P 2012-06-14 2012-06-14

Publications (1)

Publication Number Publication Date
AR087749A1 true AR087749A1 (es) 2014-04-16

Family

ID=46881120

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103217A AR087749A1 (es) 2011-09-01 2012-08-30 Anticuerpos anti-xcr1 humano

Country Status (19)

Country Link
US (1) US9371389B2 (es)
EP (1) EP2751140B1 (es)
JP (1) JP5989096B2 (es)
KR (1) KR101767717B1 (es)
CN (1) CN103764680B (es)
AR (1) AR087749A1 (es)
AU (1) AU2012302596B2 (es)
BR (1) BR112014004352A2 (es)
CA (1) CA2846370C (es)
ES (1) ES2684173T3 (es)
HK (1) HK1199038A1 (es)
IL (1) IL231075A (es)
IN (1) IN2014CN01466A (es)
MX (1) MX346560B (es)
MY (1) MY166152A (es)
PH (1) PH12014500384A1 (es)
RU (1) RU2619180C2 (es)
TW (1) TWI563004B (es)
WO (1) WO2013032032A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6208864B2 (ja) * 2013-06-24 2017-10-04 エービーエルバイオ 安定性が改善された抗体−薬物結合体およびこれの用途
SMT202200317T1 (it) * 2015-08-05 2022-09-14 Inst Nat Sante Rech Med Anticorpi anti-gpvi umana innovativi e relativi usi
US11692033B2 (en) 2017-02-03 2023-07-04 Acticor Biotech Inhibition of platelet aggregation using anti-human GPVI antibodies
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CN107312092B (zh) * 2017-05-04 2020-12-11 华南农业大学 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用
US20210130776A1 (en) * 2017-09-29 2021-05-06 The Broad Institute, Inc. Methods and compositions for modulating suppression of lymphocyte activity
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
JP7677892B2 (ja) 2018-12-28 2025-05-15 エフ． ホフマン－ラ ロシュ アーゲー 免疫応答が増幅された患者における治療的使用のためのペプチド－ｍｈｃ－ｉ－抗体融合タンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5786210A (en) 1994-02-08 1998-07-28 Schering Corporation Mammalian thymokine genes
AU2001250412A1 (en) * 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
AU2002246557A1 (en) * 2000-11-29 2002-08-06 Lifespan Biosciences, Inc. Compositions and methods related to chemokine (c motif) xc receptor 1 (ccxcr1)
US20050136033A9 (en) 2002-08-13 2005-06-23 Matthias Mack Method of treating allergen induced airway disease
WO2004072646A1 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5)
EP1698902A1 (en) * 2005-03-01 2006-09-06 DKFZ Deutsches Krebsforschungszentrum Use of XCR1 for diagnosing or monitoring of immune tolerance
CN101293924A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
EP2062592A1 (en) * 2007-11-20 2009-05-27 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten System for delivery into a XCR1 positive cell and uses thereof
CN102439163A (zh) * 2009-02-16 2012-05-02 拜奥雷克斯治疗公司 人源化抗cd20抗体及使用方法

Also Published As

Publication number Publication date
JP2014527396A (ja) 2014-10-16
RU2619180C2 (ru) 2017-05-12
ES2684173T3 (es) 2018-10-01
TW201311725A (zh) 2013-03-16
CA2846370C (en) 2019-04-23
TWI563004B (en) 2016-12-21
HK1199038A1 (en) 2015-06-19
AU2012302596B2 (en) 2016-12-01
MX346560B (es) 2017-03-24
CA2846370A1 (en) 2013-03-07
MX2014002078A (es) 2014-05-30
IN2014CN01466A (es) 2015-05-08
IL231075A0 (en) 2014-03-31
PH12014500384A1 (en) 2014-04-14
CN103764680A (zh) 2014-04-30
BR112014004352A2 (pt) 2017-03-21
AU2012302596A1 (en) 2014-03-06
CN103764680B (zh) 2016-11-23
EP2751140B1 (en) 2018-05-30
RU2014106832A (ru) 2015-08-27
MY166152A (en) 2018-06-06
EP2751140A1 (en) 2014-07-09
US20140193421A1 (en) 2014-07-10
US9371389B2 (en) 2016-06-21
IL231075A (en) 2017-08-31
JP5989096B2 (ja) 2016-09-07
KR20140054108A (ko) 2014-05-08
WO2013032032A1 (en) 2013-03-07
NZ621320A (en) 2015-11-27
KR101767717B1 (ko) 2017-08-11

Similar Documents

Publication Publication Date Title
AR087749A1 (es) Anticuerpos anti-xcr1 humano
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
MX2015013065A (es) Proteinas f de rsv de prefusion y su uso.
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
MX2021015971A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2011000768A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
PE20141162A1 (es) Anticuerpos anti-il-23
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
AR082149A1 (es) Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
MX388698B (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
EA201300130A1 (ru) Способ лечения болезни альцгеймера
ES2440393R1 (es) Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
EA201892523A1 (ru) Днк-моноклональные антитела, нацеленные на вирус гриппа
AR105800A1 (es) Polipéptidos mrka, anticuerpos anti-mrka y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure